DWTX revenueQ3 2026$100.0K
DWTX revenue was $100.0K in fiscal Q3 2026 (ended Sep 30, 2026).
Dogwood Therapeutics Inc. (DWTX) financials
For the twelve months ended Sep 30, 2026, Dogwood Therapeutics Inc. reported -$25.18M of net income.
- Net income, TTM
- -$25.18M
- Cash
- $4.95M
- Market cap
- $45.9M
FY2020FY2025
DWTX revenue and earnings growth
DWTX net incomeQ3 2026-$4.88M
DWTX net income was -$4.88M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$15.74M a year earlier. For the full fiscal 2025 it was -$34.26M, compared with -$12.35M in fiscal 2024.
DWTX EPSQ3 2026-$0.14
DWTX diluted EPS was -$0.14 in fiscal Q3 2026 (ended Sep 30, 2026). For the full fiscal 2025 it was -$7.13.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Research and development | $21.87M | $3.53M | $1.73M | $8.07M | $10.80M | $194.0K |
| Selling, general and admin | $6.10M | $8.70M | $3.72M | $4.25M | $4.85M | $9.81M |
| Operating income | -$27.97M | -$12.23M | -$5.45M | -$12.32M | -$15.64M | -$10.01M |
| Pre-tax income | -$34.04M | -$12.35M | -$5.30M | -$12.25M | -$15.96M | -$10.35M |
| Income tax | $221.1K | -$503 | - | - | - | - |
| Net income | -$34.26M | -$12.35M | -$5.30M | -$12.25M | -$15.96M | -$10.35M |
| EPS, basic | -$7.13 | -$12.52 | -$7.05 | -$27.75 | -$48.00 | -$52.50 |
| EPS, diluted | -$7.13 | -$12.52 | -$7.05 | -$27.75 | -$48.00 | -$52.50 |
| Diluted shares | 5.0M | 1.0M | 751,071 | 442,804.64 | 333,172.4 | 197,079.4 |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Cash and equivalents | $6.52M | $14.85M | $3.32M | $7.03M | $14.01M | $29.80M |
| Current assets | $8.43M | $16.54M | $4.17M | $8.37M | $15.78M | $31.47M |
| Goodwill | $12.40M | $11.81M | - | - | - | - |
| Total assets | $90.17M | $94.31M | $4.17M | $8.37M | $15.78M | $31.47M |
| Current liabilities | $3.06M | $3.18M | $358.5K | $1.04M | $1.28M | $1.53M |
| Total debt | - | - | - | - | - | $0 |
| Total liabilities | $15.27M | $30.03M | $358.5K | $1.04M | $1.28M | $1.53M |
| Shareholders' equity | $74.90M | -$10.12M | $3.81M | $7.33M | $14.50M | $29.94M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$15.62M | -$8.79M | -$4.87M | -$11.47M | -$15.69M | -$3.90M |
| Investing cash flow | - | $3.76M | - | - | - | - |
| Financing cash flow | $7.28M | $16.70M | $1.16M | $4.49M | -$97.6K | $33.38M |
| Stock-based compensation | $355.6K | $476.0K | $620.0K | $582.7K | $322.9K | $7.43M |
Key ratios
Income statement
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $100.0K | - | - | - | - | - | - | - | - | - | - | - |
| Cost of revenue | $88.1K | - | - | - | - | - | - | - | - | - | - | - |
| Gross profit | $11.9K | - | - | - | - | - | - | - | - | - | - | - |
| Research and development | $3.35M | $3.25M | $2.67M | $2.34M | $14.52M | $2.57M | $2.44M | $2.32M | $535.2K | $336.1K | $343.7K | $298.3K |
| Selling, general and admin | $1.58M | $1.63M | $2.41M | $1.47M | $1.29M | $1.35M | $1.99M | $5.23M | $1.77M | $733.7K | $970.4K | $839.8K |
| Operating income | -$4.92M | -$14.06M | -$5.08M | -$3.81M | -$15.81M | -$3.92M | -$4.43M | -$7.54M | -$2.30M | -$1.07M | -$1.31M | -$1.14M |
| Pre-tax income | -$4.88M | -$14.01M | -$4.99M | -$3.75M | -$15.75M | -$3.81M | -$10.73M | -$7.73M | -$2.28M | -$1.05M | -$1.29M | -$1.10M |
| Net income | -$4.88M | -$11.53M | -$4.99M | -$3.78M | -$15.74M | -$3.81M | -$10.92M | -$7.73M | -$2.28M | -$1.05M | -$1.29M | -$1.10M |
| EPS, basic | -$0.14 | -$0.34 | -$0.15 | - | -$8.20 | -$1.99 | -$8.45 | - | -$2.05 | -$1.15 | -$1.68 | -$1.43 |
| EPS, diluted | -$0.14 | -$0.34 | -$0.15 | - | -$8.20 | -$1.99 | -$8.45 | - | -$2.05 | -$1.15 | -$1.68 | -$1.43 |
| Diluted shares | 34.1M | 34.1M | 33.5M | - | 1.9M | 1.9M | 1.4M | - | 1.1M | 916,031 | 770,317 | - |
Balance sheet
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $4.95M | $9.61M | $13.23M | $6.52M | $10.13M | $13.40M | $17.54M | $14.85M | $2.04M | $3.02M | $2.38M | $3.32M |
| Current assets | $6.04M | $11.03M | $15.00M | $8.43M | $11.66M | $14.70M | $19.16M | $16.54M | $2.28M | $3.64M | $3.22M | $4.17M |
| Goodwill | $11.98M | $11.96M | $12.19M | $12.40M | $12.21M | $12.46M | $11.82M | $11.81M | - | - | - | - |
| Total assets | $75.61M | $80.50M | $95.21M | $90.17M | $91.99M | $96.69M | $96.98M | $94.31M | $2.28M | $3.64M | $3.22M | $4.17M |
| Current liabilities | $2.17M | $2.83M | $2.56M | $3.06M | $2.60M | $1.89M | $2.58M | $3.18M | $1.33M | $500.1K | $570.1K | $358.5K |
| Total liabilities | $11.47M | $12.13M | $14.58M | $15.27M | $14.61M | $14.15M | $14.24M | $30.03M | $1.33M | $500.1K | $570.1K | $358.5K |
| Shareholders' equity | $64.13M | $68.37M | $80.62M | $74.90M | $7.26M | $6.88M | $7.09M | -$10.12M | $949.4K | $3.14M | $2.65M | $3.81M |
Cash flow
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$4.64M | -$3.61M | -$4.59M | -$3.64M | -$3.27M | -$4.03M | -$4.68M | -$6.13M | -$910.1K | -$811.7K | -$937.4K | -$1.47M |
| Financing cash flow | $50 | $23 | $11.29M | $32.6K | $0 | -$120.1K | $7.37M | $15.32M | -$70.2K | - | - | $0 |
| Stock-based compensation | $558.4K | $543.2K | $449.4K | $157.9K | $48.3K | $65.0K | $84.5K | $93.8K | $94.3K | $148.9K | $139.0K | $148.3K |
Key ratios
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 11.9% | - | - | - | - | - | - | - | - | - | - | - |
| Operating margin | -4917.3% | - | - | - | - | - | - | - | - | - | - | - |
| Net margin | -4882.9% | - | - | - | - | - | - | - | - | - | - | - |
| Current ratio | 2.78 | 3.89 | 5.86 | 2.76 | 4.49 | 7.80 | 7.43 | 5.21 | 1.71 | 7.27 | 5.66 | 11.62 |
Source: XBRL data Dogwood Therapeutics Inc. files with the SEC, latest filing dated Nov 6, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures and share counts are restated for stock splits the filings show: 1-for-25, first reported Nov 8, 2024.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
DWTX peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| DWTX | - | - | -$25.18M | - | $45.9M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.33T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $679.13B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $518.44B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $366.73B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $312.35B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $293.69B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $191.40B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $183.23B |
DWTX FAQ
4 questionsIs DWTX profitable?
No. Dogwood Therapeutics Inc. reported a net loss of $25.18M for the twelve months ended Sep 30, 2026.How much cash and debt does DWTX have?
Dogwood Therapeutics Inc. reported $4.95M in cash and cash equivalents on its most recent balance sheet in SEC filings.When did DWTX last report financial results?
The latest statements here come from Dogwood Therapeutics Inc.'s 10-Q filed on Nov 6, 2026, covering the period ended Sep 30, 2026.Where does this DWTX financial data come from?
Quantisnow builds these statements from the structured XBRL data Dogwood Therapeutics Inc. files with the SEC. It is provided for information only and is not investment advice.